2009
DOI: 10.1159/000189194
|View full text |Cite
|
Sign up to set email alerts
|

Pimecrolimus Reduces Eosinophil Activation Associated with Calcium Mobilization

Abstract: Background: Pimecrolimus is a calcineurin inhibitor that inhibits T cell and mast cell activation and effectively treats atopic dermatitis. However, its effects on eosinophils, a cell type implicated in allergic disease pathology, are unknown. Therefore, we examined the effects of pimecrolimus on eosinophil superoxide anion production, degranulation and survival. Methods: Purified eosinophils from normal or atopic donors were incubated with serial dilutions of pimecrolimus (μM to nM) and then stimulated with p… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
12
0

Year Published

2009
2009
2022
2022

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 14 publications
(12 citation statements)
references
References 55 publications
(38 reference statements)
0
12
0
Order By: Relevance
“…Eosinophil degranulation has been implicated in the pathology of bronchial asthma and is closely associated with disease activity [15,16,17]. Superoxide generation is another important proinflammatory function of eosinophils [18] and might induce oxidative tissue damage [19,20]. Actually, oxidative stress has been shown to increase in patients with asthma [21].…”
Section: Discussionmentioning
confidence: 99%
“…Eosinophil degranulation has been implicated in the pathology of bronchial asthma and is closely associated with disease activity [15,16,17]. Superoxide generation is another important proinflammatory function of eosinophils [18] and might induce oxidative tissue damage [19,20]. Actually, oxidative stress has been shown to increase in patients with asthma [21].…”
Section: Discussionmentioning
confidence: 99%
“…Immobilized IgG, IgA, and secretory IgA (sIgA) induce eosinophil degranulation [13,23], and various lipid mediators (such as PAF) and cytokines (such as IL-5) also activate eosinophils [21]. Furthermore, activated eosinophils release granule proteins (for example major basic protein and EDN), lipid mediators, reactive oxygen intermediates, cytokines and enzymes [2].…”
Section: Discussionmentioning
confidence: 99%
“…Immediately after eosinophils were placed, the absorbance at 550 nm was analyzed in a Thermomax plate reader (Molecular Devices, Sunnyvale, Calif., USA) followed by readings every 15–30 min. Conversion of absorbance to nanomoles of cytochrome c reduced per 1 × 10 6 eosinophils used the following equation: 19.1 × (absorbance – absorbance time 0 )/0.05 = nmol cytochrome c reduced/10 6 cells [20,21]. …”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…[27] At nanomolar concentrations, pimecrolimus inhibits the production and release of inflammatory cytokines (interferon-g, IL-2, IL-4, IL-5, IL-10, and tumor necrosis factor-a); [23][24][25]28,29] the drug also inhibits the release of inflammatory cytokines and mediators (e.g. [28] Pimecrolimus also inhibits superoxide anion production and eosinophil-derived neurotoxin release by »30-50% [31] and increases keratinocyte expression of antimicrobial peptides and the capacity to inhibit Staphylococcus aureus growth. [30] Other effects of pimecrolimus on human skin include reductions in the expression of cleaved caspase-3 in the epidermis and Fas receptor expression on keratinocytes, [29] and reduced lymphocyte and eosinophil counts.…”
Section: Mechanism Of Actionmentioning
confidence: 99%